Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Hims & Hers Health (HIMS) stock hit a new all-time high on Thursday as retail investors have taken interest in the telehealth ...

Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...

The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...

Isomorphic Labs, a spin-off from DeepMind, is applying AI-first principles to drug discovery rather than just protein ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

Shortly after Hims & Hers aired its controversial Super Bowl ad promoting its compounded GLP-1 offerings, Novo Nordisk has ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...